This company has been marked as potentially delisted and may not be actively trading. Marinus Pharmaceuticals (MRNS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock Get the Latest News and Ratings for MRNS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Marinus Pharmaceuticals and its competitors. Enter your email to sign up for newsletter Sign Up MRNS Analyst Ratings Over TimeTypeCurrent Forecast7/12/24 to 7/12/251 Month Ago6/12/24 to 6/12/253 Months Ago4/13/24 to 4/13/251 Year Ago7/13/23 to 7/12/24Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)2 Buy rating(s)4 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)8 Hold rating(s)3 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$3.92$4.79$4.79$13.79Forecasted Upside613.29% Upside771.56% Upside771.56% Upside906.26% UpsideConsensus RatingHoldHoldHoldModerate Buy MRNS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MRNS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Marinus Pharmaceuticals Stock vs. The CompetitionTypeMarinus PharmaceuticalsMedical CompaniesS&P 500Consensus Rating Score 2.40 2.80 2.54Consensus RatingHoldModerate BuyModerate BuyPredicted Upside613.29% Upside8,634.01% Upside10.52% UpsideNews Sentiment RatingNeutral NewsSee Recent MRNS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/14/2024Cantor Fitzgerald3 of 5 stars Reiterated RatingOverweight ➝ Overweight$4.00 ➝ $4.00+1,214.45%11/14/2024HC Wainwright1 of 5 starsD. TsaoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00+561.58%10/25/2024TD Cowen4 of 5 starsJ. ThomeSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold10/25/2024Royal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetSector Perform ➝ Sector Perform$3.00 ➝ $1.00+203.02%10/25/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy ➝ Hold$5.00 ➝ $0.50+68.92%10/24/2024Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. LeeSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/24/2024JMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. ButlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform9/30/2024EF Hutton Acquisition Co. ISubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. KolbertSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy9/23/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeMarket Perform ➝ Outperform$6.00+261.44%8/14/2024LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingM. HigginsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral Get the Latest News and Ratings for MRNS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 4/16/2024Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ NeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:09 PM ET. MRNS Forecast - Frequently Asked Questions What is Marinus Pharmaceuticals' forecast for 2025? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Marinus Pharmaceuticals is $3.92, with a high forecast of $10.00 and a low forecast of $0.50. Should I buy or sell Marinus Pharmaceuticals stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 7 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNS, but not buy additional shares or sell existing shares. Does Marinus Pharmaceuticals's stock price have much upside? According to analysts, Marinus Pharmaceuticals's stock has a predicted upside of 613.29% based on their 12-month stock forecasts. Do Wall Street analysts like Marinus Pharmaceuticals more than its competitors? Analysts like Marinus Pharmaceuticals less than other "medical" companies. The consensus rating for Marinus Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNS compares to other companies. Stock Forecasts and Research Tools Related Companies Upexi Stock Forecast Protalix BioTherapeutics Stock Forecast BioHarvest Sciences Stock Forecast Genelux Stock Forecast Protara Therapeutics Stock Forecast Atossa Genetics Stock Forecast TuHURA Biosciences Stock Forecast C4 Therapeutics Stock Forecast ANIXA BIOSCIENCES Stock Forecast Milestone Pharmaceuticals Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:MRNS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.